Literature DB >> 30296541

Future considerations for clinical dermatology in the setting of 21st century American policy reform: Corporatization and the rise of private equity in dermatology.

Sailesh Konda1, Joseph Francis2, Kiran Motaparthi2, Jane M Grant-Kels3.   

Abstract

Within the past 2 decades, for-profit financial groups have become increasingly involved in health care. Outlier dermatology practices with high volumes of well-reimbursed procedures are attractive to consolidation backed by private equity. With fewer choices for independent or group private practice, junior dermatologists are increasingly seeking employment without ownership in private equity-backed corporate groups whose primary fiscal responsibility lies with their investors. Medicare's response to corporatization and consolidation has already changed the practice of dermatopathology. Dermatologists should be aware of this history, given the ability of corporations and private equity groups to shape the present and future of our field.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Keywords:  consolidation; corporatization; dermatology; dermatopathology; outlier practice patterns; private equity; venture capital

Mesh:

Year:  2018        PMID: 30296541     DOI: 10.1016/j.jaad.2018.09.052

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Private equity and its effect on patients: a window into the future.

Authors:  Sajith Matthews; Renato Roxas
Journal:  Int J Health Econ Manag       Date:  2022-05-23

2.  Practice Consolidation in Otolaryngology: The Decline of the Single-Provider Practice.

Authors:  Humzah A Quereshy; Brooke A Quinton; Jeremy S Ruthberg; Nicole C Maronian; Todd D Otteson
Journal:  OTO Open       Date:  2022-02-25

3.  Changes in Hospital Income, Use, and Quality Associated With Private Equity Acquisition.

Authors:  Joseph D Bruch; Suhas Gondi; Zirui Song
Journal:  JAMA Intern Med       Date:  2020-11-01       Impact factor: 44.409

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.